A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action-Reference-Cited by-同舟云学术

A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action

Published:2014-03 Issue: Volume:156 Page:24-35
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Naughton Marie,Clarke Gerard,O′Leary Olivia F.,Cryan John F.,Dinan Timothy G.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference132 articles.

1. Safety and efficacy of repeated dose intravenous ketamine for treatment resistant depression;Aan het Rot;Biol. Psychiatry,2010

2. Ketamine and depression: where do we go from here?;Aan het Rot;Biol. Psychiatry,2012

3. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting;Abdallah;J. ECT,2012

4. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synaptic and mTOR;Akinfiresoye;Psychopharmacology (Berl),2013

5. Does increasing the ratio of AMPA-to-NMDA receptor medicated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests;Andreasen;Neurosci. Lett.,2013

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression;Asian Journal of Psychiatry;2024-09

2. A prospective open-label study to evaluate the effectiveness of intravenous ketamine as an adjunct in treating severe depression;Middle East Current Psychiatry;2024-04-23

3. Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine;Frontiers in Pharmacology;2023-11-27

4. New Approach for Treatment-Resistant Depression;Old Protein, New Medicine - Brain-Derived Neurotrophic Factor [Working Title];2023-10-07

5. Hippocampal pituitary adenylate cyclase–activating polypeptide mediates rapid antidepressant-like effects of Yueju pill;Neuropeptides;2023-10